As the efficacy of T‐DM1 in HER2‐positive UBC or pancreatic cancer/cholangiocarcinoma is unknown, KAMELEON sought to assess whether patients with these tumor types would benefit from T‐DM1. Here, ERBB2 is linked to neoplasm.